Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.37
(
1.68%
)
Bitcoin
71,156.63
(
-0.12%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 129465

Wednesday, 10/26/2011 11:55:03 AM

Wednesday, October 26, 2011 11:55:03 AM

Post# of 257257

Could we possibly see a fixed-dose formulation [of boosted Reyataz + Truvada]?

There is no reason I know of why there should not be such an option.

How is Complera doing?

We’ll find out tomorrow afternoon when GILD reports 3Q11 results. I don’t expect 3Q11 Complera sales to amount to much insofar as the drug was on the US market for only half the quarter and it is not yet available for sale in the EU.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now